Therefore, the approaches discussed in Section 2.2 and Section 3.5, focusing on targeting MYCN and ALK, may be used not only to target tumor growth, but to alleviate immune evasion mechanisms, and their effect could be further potentiated by combining them with immunotherapeutic approaches. Here, MYCN is linked to neoplasm.